Yes, clearly you have assessed my post correctly. But even if all the ducks were lined up, instos would be unlikely to look at a company with a SP under 10c.
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%
